NCT01924845 - BMN 701 Phase 3 in rhGAA Exposed Subjects With Late Onset Pompe Disease (INSPIRE Study) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

September 12, 2016

Study Completion Date

September 12, 2016

Conditions

Late-onset Pompe Disease

Interventions

DRUG

BMN 701

BMN 701 20 mg/kg for intravenous administration over approximately 4 hours every 2 weeks over a 24-week Treatment Period (total of 13 doses), and every 2 weeks over a 240-week Extension Period (up to 120 additional doses).

Trial Locations (22)

13005

CHU de la Timone, Marseille

20133

Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, Milan

27710

Duke University Medical Center, Durham

32610

University of Florida, Gainesville

36110

Washington University, St Louis

43210

The Ohio State University - Wexner Medical Center, Columbus

48149

Universitätsklinikum Münster, Münster

66160

University of Kansas Medical Center, Kansas City

84132

University of Utah, Salt Lake City

85028

Neuromuscular Research Centre, Phoenix

92380

Hôpital Raymond Poincaré, Garches

92868

University of California, Irvine, Orange

98125

"Azienda Ospedaliera Universitaria Policlinico G. Martino - Messina", Messina

Unknown

Antwerp University Hospital (UZA), Edegem

Villa Metabolica, ZKJM MC University Mainz, Mainz

Klinikum der Universität München, München

University Hospital Birmingham, Birmingham

National Hospital for Neurology and Neurosurgery, London

3015 GJ

Erasmus MC University Medical Center, Rotterdam

4200-319

Centro Hospitalar de Sao Joao, EPE, Porto

NW3 2QG

Royal Free Hospital, London

M5 5AP

Salford Royal NHS Foundation Trust, Salford